Last reviewed · How we verify

NCT04644952

The Rise in Robotic Atypical Segmentectomies

Recruiting now Last updated 5 March 2026
What this trial tests

trial testing Electronic Health Record Review in Lung Carcinoma in 600 participants. Currently enrolling.

Timeline
15 September 2020
Primary endpoint
30 April 2027
30 April 2027

Quick facts

Lead sponsorM.D. Anderson Cancer Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment600
Start date15 September 2020
Primary completion30 April 2027
Estimated completion30 April 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the increased rate of robotic atypical segmentectomies. Segmentectomy refers to removing a section of a lobe of the lung. Reviewing patients' data retrospectively may help researchers determine whether robotic surgery has led to an increase in atypical segmentectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Electronic Health Record Review

Trials testing the same drug.

Other recruiting trials for Lung Carcinoma

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04644952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing